 |
|
|
| |
Genotypic Characterisation of Filibuvir Resistance in Patients Receiving Four Weeks Co-administration of Filibuvir with pegIFN/RBV(12 Week Analysis)
|
| |
| |
Reported by Jules Levin
EASL Apr 14-18 2010 Vienna Austria
J Mori1, JL Hammond2, S Srinivasan2
S Jagannatha2, E Van der Ryst1
1Pfizer Global Research & Development, Sandwich, Kent, UK2Pfizer Global Research & Development, New London, CT, USA
Shi ST, et al. Antimicrob Agents Chemother2009;53:2544-2552
|
| |
|
|
|
|
|
